Discovery & Development of S-4321, a Novel PD-1 FcgRIIb Dual Cell Bidirectional (DcB) Agonist Antibody
Time: 9:00 am
day: Conference Day Two
Details:
• Current approaches to checkpoint agonism in autoimmunity
• Concept of Dual Cell Bidirectional antibodies
• Discovery and development of S-4321, a novel PD-1 FcgRIIb dual cell bidirectional (DcB) agonist antibody
